loading page

Indomethacin is an effective treatment in adults and children with bone Langerhans cell histiocytosis (LCH)
  • +5
  • Daniela De Benedittis,
  • Sara Mohamed,
  • Lorenzo Rizzo,
  • Michelina Santopietro,
  • Giovanna Palumbo,
  • Luisa Cardarelli,
  • Mario Roggini,
  • Fiorina Giona
Daniela De Benedittis
Sapienza University of Rome
Author Profile
Sara Mohamed
Sapienza University of Rome
Author Profile
Lorenzo Rizzo
Niguarda Hospital Department of Niguarda Cancer Center
Author Profile
Michelina Santopietro
San Camillo Forlanini Hospital
Author Profile
Giovanna Palumbo
Sapienza University of Rome
Author Profile
Luisa Cardarelli
Sapienza University of Rome
Author Profile
Mario Roggini
Sapienza University of Rome
Author Profile
Fiorina Giona
Sapienza University of Rome
Author Profile

Abstract

Sixty-three patients with LCH (54 adults, 9 children), with unifocal or multifocal bone lesions were treated with indomethacin. All but one patient achieved a response, that was complete in 52% of them. Overall, 5-year reactivation-free survival was 72%, significantly higher in patients treated with indomethacin as first-line (81.7% vs 52.5%; p=0.01); in those who received indomethacin as single agent (80.5% vs 36.5%, p=0.005); and in those with unifocal disease (90.9% vs 48.1%, p=0.003). Our results confirmed the efficacy of indomethacin in bone LCH both as front-line treatment and after reactivations, in localized, or more extended disease, with minimal side effects.